Heavy snow and difficult travel expected again, heaviest snow in southern Minnesota

MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all. 

Turn Up Your Support

There's enough concern over a widely-used heartburn drug that its maker has stopped distributing the generic version. You may know ranitidine by its brand name Zantac. Earlier this month the Food and Drug Administration reported it 

So, what do people who take the medication need to know?

“You constantly have to weigh the benefit of being on [certain medications] versus the potential harms that it may cause. In a case like this, because there are easy alternatives, I think you say, look, it’s probably not worth taking an even small chance with this,” Dr. Jon Hallberg, medical director of the 

University of Minnesota Physicians Mill City Clinic

But he said the level of carcinogen found may be low enough that patients who only respond to ranitidine take that risk. He said people in that situation should talk to their doctors.

To hear more, including which medications would work as a replacement for ranitidine, hit play on the audio player above.

Health

Shows

All Things Considered

MPR News Programs and Podcasts

Hallberg's Picture of Health

Tom Crann

Host

Dr. Jon Hallberg

Guest

Our weekly medical analyst, Dr. Jon Hallberg, breaks down what you need to know about a recent FDA finding that ranitidine, known by the brand name Zantac, includes trace amounts of a known carcinogen.

FDA found traces of a known carcinogen in a popular heartburn medication — now what?

Go Deeper.

Like this?